Private Equity Looking for Interns - Gilde Healthcare

Private Equity Looking for Interns

August 3, 2017

Gilde Healthcare Services, a lower mid-market buy-out fund focused on Benelux and Germany, is looking for a student intern that is able to support the investment team with its activities.

Given the compact investment team, the intern will have the opportunity to take an integral role in a deal team. The intern will have the opportunity to engage in many parts of the investment process, with an emphasis on the deal origination phase. Strong analytical skills, an excellent track record and an entrepreneurial spirit are therefore required. We assume fluency in English and either Dutch or German. A previous internship in corporate finance, strategy consultancy or private equity is appreciated. You will work 3 (or more) months in the city of Utrecht as member of our investment team.

More information: More information on Gilde Healthcare: gildehealthcare.com More information on this position: Mr. T. Klein Robbenhaar, robbenhaar@gildehealthcare.com When interested, please send your resume and concise motivational email and we will be in contact with you.

 

 

Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiveness

Big Health has become the first digital therapeutics company to receive guidance from the National Institute for Health and Care Excellence (NICE), which has recommended Sleepio as a cost-saving option for treating insomnia in a move that heralds...
May 20, 2022

Gilde Healthcare portfolio company Synexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics to expand bioanalysis capabilities in clinical drug development

Gilde Healthcare portfolio company Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, has today announced that it has acquired Syrinx Bioanalytics, a bioanalytical CRO based in Turku, Finland. The move...
May 19, 2022

Gilde Healthcare company Amphista Therapeutics enters a up to $1.0 billion strategic collaboration with Merck

Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39 million ($44 million) in combined upfront and R&D funding...
May 4, 2022